|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.02|
ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it has been notified by The NASDAQ Stock Market (“NASDAQ”) that the listing of its common stock will be transferred from The NASDAQ Global Market to The ...
ARYx Therapeutics, Inc. (NASDAQ:ARYX) today reported on its on-going strategic corporate efforts to optimize the value of its assets on behalf of the company’s stockholders.
Clinical trial failures, poor sales and crushing debt pummeled shares of Vermillion, Oxigene and Angiotech in 2010.
ARYx Therapeutics, Inc. (NASDAQ:ARYX) today provided an update on its business operations and released its financial results for the third quarter of 2010.
ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that ARYx was notified October 5, 2010 by the staff of the NASDAQ Stock Market that it has not regained compliance with the $50 million minimum market ...
ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it has secured bridge financing to allow ARYx time and resources to potentially complete a transaction that could create significant value for stockholders.
ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that Peter G.
ARYx Therapeutics, Inc. (NASDAQ:ARYX) today reported results of operations and provided an update on its business activities for the first quarter ended March 31, 2010.
ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced today that a conference call to discuss first quarter 2010 results and to provide a general business update will be held on Thursday, May...
ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it will present at the Cowen and Company 30 th Annual Health Care Conference in Boston on March 9, 2010 at 1:30 pm Eastern.
Biotech watchdog Adam Feuerstein addresses readers' questions about BioSante and other healthcare stocks.
ARYx Therapeutics Inc. (NASDAQ: ARYX), a biopharmaceutical company, today announced that it has retained Cowen and Company to explore strategic options for ARYx.
Several small-cap stocks were poised to move on above-average volume during Thursday's session.
Biotechnology company ARYx Therapeutics reports smaller 2nd-quarter loss, no revenue
Debra Borchardt and co-host Liz Trotta break down the market with guests David Peltier, Scott Moritz, and Adam Feuerstein.
Amgen is up big on its denosumab victory, while Aryx Therapeutics is down bigger on new blood-clotting data.
Bank of America and Citigroup are holding the top spots on TheStreet.com's stock-search list today. New entries to the list include Cell Therapeutics, ARYx Therapeutics, Hemispherx Biopharma and Boeing.
A quick and dirty guide to upcoming clinical trial dates for drug and biotech companies.
Aryx Therapeutics' 1st-quarter loss widens on revenue drop after partnership ends
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.